国内哪能买到厄达替尼？

Where can I buy Erdafitinib in China? It is currently on the market in Hong Kong but not yet on the mainland. Patients cannot buy erdafitinib in the mainland.

Erdafitinib, trade name Balversa, was approved by the US FDA on April 12, 2019, for the treatment of patients with locally advanced or metastatic bladder cancer who have FGFR3 or FGFR2 gene mutations and have progressed during or after platinum-containing chemotherapy, including patients with disease progression within 12 months of neoadjuvant or adjuvant platinum chemotherapy.

Bladder cancer refers to malignant tumors that occur on the bladder mucosa. It is the most common malignant tumor of the urinary system and one of the ten most common tumors in the body. Accounting for the first place in the incidence of urogenital tumors in my country, bladder cancer can occur at any age, even in children. Its incidence increases with age, with the highest incidence occurring between the ages of 50 and 70.

The clinical trial enrolled 87 patients with locally advanced or metastatic bladder cancer who had disease progression during or after at least one chemotherapy regimen and who carried FGFR3 gene mutations or FGFR gene fusions. The results of the treatment were: the objective response rate ORR (tumor shrinkage by more than 30%) for all patients was 32.2%, the complete response rate CR (tumor disappeared completely) was 2.3%, the partial response rate PR was 29.9%, and the median sustained response time DOR was 5.4 months. For different types of genetic mutations, the therapeutic effects are different. For patients with FGFR3 point mutations, the objective response rate ORR after treatment is 40.6%; for patients with FGFR3 fusion mutations, the objective response rate ORR is 11.1%; and for patients with FGFR2 fusion mutations, the ORR is 0%, which means the treatment is ineffective.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: